Show simple item record

dc.contributor.authorItzhaki, Ruth F.; email: ruth.itzhaki@manchester.ac.uk
dc.date.accessioned2021-06-22T22:31:33Z
dc.date.available2021-06-22T22:31:33Z
dc.date.issued2021-06-21
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625016/vaccines-09-00679-v2.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625016/additional-files.zip?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625016/vaccines-09-00679.xml?sequence=4
dc.identifier.citationVaccines, volume 9, issue 6, page e679
dc.identifier.urihttp://hdl.handle.net/10034/625016
dc.descriptionFrom MDPI via Jisc Publications Router
dc.descriptionHistory: accepted 2021-06-17, pub-electronic 2021-06-21
dc.descriptionPublication status: Published
dc.description.abstractThis review describes investigations of specific topics that lie within the general subject of HSV1’s role in AD/dementia, published in the last couple of years. They include studies on the following: relationship of HSV1 to AD using neural stem cells; the apparent protective effects of treatment of HSV1 infection or of VZV infection with antivirals prior to the onset of dementia; the putative involvement of VZV in AD/dementia; the possible role of human herpes virus 6 (HHV6) in AD; the seemingly reduced risk of dementia after vaccination with diverse types of vaccine, and the association shown in some vaccine studies with reduced frequency of HSV1 reactivation; anti-HSV serum antibodies supporting the linkage of HSV1 in brain with AD in APOE-ε4 carriers, and the association between APOE and cognition, and association of APOE and infection with AD/dementia. The conclusions are that there is now overwhelming evidence for HSV1’s role—probably causal—in AD, when it is present in brain of APOE-ε4 carriers, and that further investigations should be made on possible prevention of the disease by vaccination, or by prolonged antiviral treatment of HSV1 infection in APOE-ε4 carriers, before disease onset.
dc.languageen
dc.publisherMDPI
dc.rightsLicence for this article: https://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 2076-393X
dc.subjectAlzheimer’s disease
dc.subjectherpes simplex virus type 1 (HSV1)
dc.subjectapolipoprotein E (APOE)
dc.subjectbrain
dc.subjectantivirals
dc.titleOverwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer’s Disease (AD); Underwhelming Evidence against
dc.typearticle
dc.date.updated2021-06-22T22:31:33Z
dc.date.accepted2021-06-17


Files in this item

Thumbnail
Name:
vaccines-09-00679-v2.pdf
Size:
926.0Kb
Format:
PDF
Thumbnail
Name:
additional-files.zip
Size:
125.4Kb
Format:
Unknown
Thumbnail
Name:
vaccines-09-00679.xml
Size:
4.735Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record